Phase II Study of Rituximab Combined With ESHAP in Patients With Relapse or Refractory DLBCL.

Trial Profile

Phase II Study of Rituximab Combined With ESHAP in Patients With Relapse or Refractory DLBCL.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2012

At a glance

  • Drugs Rituximab (Primary) ; Cisplatin; Cytarabine; Etoposide; Methylprednisolone
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms ESHAP-DLBCL
  • Most Recent Events

    • 18 Jan 2011 Status changed from recruiting to completed according to ClinicalTrials.gov.
    • 25 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top